Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Children with CD have a more-complicated disease course compared with adult patients. The primary goal of pediatric CD treatment is to induce and maintain remission as quickly as possible. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. However, this scenario has largely changed, and physicians increasingly initiate treatment with TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira). The non-TNF biologics, including Takeda’s Entyvio and Janssen’s Stelara, also have a growing market share.
Real World data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants
Key Analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Already a Client? Log in to access this report.
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.